(UroToday.com) Dr. Kenneth Pienta gave a short overview of prostate-specific membrane antigen (PSMA) radioligand therapy. PSMA is a transmembrane carboxypeptidase highly expressed on prostate cancer cells. Its expression has been observed in more than 95% of prostate cancer tumors. There is a direct correlation between PSMA expression levels and tumor aggressiveness.
